NuCana (NASDAQ:NCNA) Announces Quarterly Earnings Results

NuCana (NASDAQ:NCNA) announced its quarterly earnings data on Thursday. The company reported ($0.32) EPS for the quarter, topping analysts’ consensus estimates of ($2.43) by $2.11, Zacks reports.

NuCana Trading Down 4.5 %

Shares of NuCana stock traded down $0.04 on Thursday, reaching $0.81. 30,468 shares of the stock were exchanged, compared to its average volume of 419,991. The firm has a market capitalization of $2.13 million, a PE ratio of -0.08 and a beta of 0.89. NuCana has a 1-year low of $0.75 and a 1-year high of $10.79. The business has a fifty day moving average price of $0.98 and a two-hundred day moving average price of $1.57.

NuCana Company Profile

NuCana plc, a clinical-stage biopharmaceutical company, engages in the development of medicines to treat patients with cancer. It applies its ProTide technology to transform prescribed chemotherapy agents and nucleoside analogs into medicines. The company, through its technology, is developing ProTides medicines to overcome the limitations of nucleoside analogs and generate much higher concentrations of anti-cancer metabolites in cancer cells.